Healthier Capital has closed its $220 million inaugural venture fund, which was oversubscribed, raising capital from universities, endowments, family offices, healthcare organizations, and other investors as it looks to back early-stage companies at the intersection of healthcare and technology.
The Menlo Park-based firm said Fund 1 will focus on technology-powered innovators applying AI and modernized information technologies to healthcare’s largest operational and clinical challenges, with an emphasis on building businesses that can scale impact and improve outcomes.
Healthier Capital was founded by Amir Dan Rubin, who previously held senior leadership roles across healthcare delivery and managed care, including serving as CEO of Amazon | One Medical and earlier as chair and CEO of One Medical through its 2020 IPO and subsequent acquisition by Amazon in 2023. Rubin has also served as an executive vice president at Optum/UnitedHealth Group and held leadership roles at Stanford Health Care, UCLA Health, and SUNY Stony Brook.
The firm’s partners include Gregor Kevrekian, Aman Mahajan, MD/PhD, and Eric Epstein, who collectively bring backgrounds spanning healthcare operators, investors, and advisors, with experience tied to organizations including CVS Health, Aetna and Aetna Ventures, UPMC and UPMC Enterprises, UCLA Health and UCLA School of Medicine, Santé Ventures, McKinsey & Company and multiple healthcare startups.
Healthier Capital said it works closely with portfolio companies to accelerate performance by leveraging a network across health systems, health plans, technology companies, policymakers, and universities. The firm highlighted involvement with boards and commercial guidance across several investments.
The fund’s portfolio includes Hyro, which develops conversational AI agents for healthcare enterprises; Qualified Health, which offers a platform for deploying generative AI applications with monitoring and governance; and Ezra, an AI-imaging preventive health company that was acquired by Function Health in May 2025. Additional portfolio highlights cited by the firm include Medeloop, Daymark Health, Amae Health, Octave Health, Diploid Genomic,s and Zarminali Pediatrics.
Healthier Capital also noted external recognition for its portfolio companies, including appearances on CB Insights’ Digital Health 50 list for 2025 and finalist placements in the 2025 Fierce Healthcare Innovation Awards.
KEY QUOTES:
“At Healthier Capital, we are focused on delivering healthier outcomes for all, partnering with technology-powered innovators to deliver transformative impact and significant value creation. At Healthier Capital, we align our health-tech venture fund with outstanding innovators, health ecosystem colleagues, and fund partners to accelerate healthcare innovation through AI and modernized information technologies deployed in highly effective business models.”
Amir Dan Rubin, CEO & Founding Managing Partner, Healthier Capital
“The Healthier Capital team has been there, done that in health-tech. In my opinion, Healthier Capital has the most accomplished team of healthcare operators in the venture capital space right now. The Healthier Capital team has been instrumental in Ezra’s success—co-leading our prior round, providing guidance on our board, helping us advance commercial opportunities, and delivering critical support through our recent acquisition.”
Emi Gal, Founder & CEO, Ezra
“Healthier Capital has been incredibly impactful in our tremendous progress. Beyond leading our last round and providing critical insights on our board, Healthier Capital brings deep health-tech experience and an unparalleled industry-wide network as Hyro deploys responsible AI agents across healthcare enterprises.”
Israel Krush, CEO, Hyro
“The Healthier Capital team is uniquely positioned to partner with us as co-founder and lead our funding round as we combine advanced AI approaches with cutting-edge genomics and imaging to help healthcare organizations better diagnose diseases, deliver treatments, and develop new therapies. We find Healthier Capital’s deep experience in healthcare delivery, scientific and clinical enterprises, and its wide network across the health-tech ecosystem to be extremely differentiated as we sought a best-in-class strategic partner for our company.”
J. Craig Venter, Human Genome Project Pioneer
